# Cardiogen

> Synthetic Ala-Glu-Asp-Arg tetrapeptide studied as a cardiac-tissue bioregulator.

- Also known as: Ala-Glu-Asp-Arg, AEDR tetrapeptide
- Class: Bioregulators, Healing & Repair
- FDA approved: No
- Canonical page: https://www.americanpeptide.com/catalog/cardiogen

## Overview

Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) in the Khavinson short-peptide bioregulator series, studied for effects on myocardial tissue.

Cardiogen (Ala-Glu-Asp-Arg) is the heart-directed member of the defined short-peptide bioregulator family, studied in the context of age-related myocardial decline in the originating research tradition.

Reported research examined cardiomyocyte markers and recovery endpoints in cardiac models, consistent with the class hypothesis of tissue-selective transcriptional modulation. Evidence is concentrated in one research tradition with limited independent replication, and it is not FDA-approved.

## Mechanism

Proposed gene-regulatory modulation of myocardial gene expression.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular weight | 489.5 Da |

## Sequence

```
AEDR
```

## Research areas

Studied in: Cardiac repair, Aging biology, Peptide bioregulators.

Guides on this site:

- [Wound Healing & Tissue Repair](https://www.americanpeptide.com/research-areas/wound-healing): Regenerative peptides studied for soft-tissue, tendon, and vascular repair.
- [Longevity & Aging](https://www.americanpeptide.com/research-areas/longevity-aging): Peptides studied across the aging axis — senescence, NAD+, and resilience.
- [Peptide Bioregulators](https://www.americanpeptide.com/research-areas/bioregulators): Short, tissue-specific peptides proposed to regulate gene expression — the Khavinson series.

## Key research

- Cardiac focus — studied for effects on myocardial tissue and recovery markers in preclinical cardiac models.
- Class mechanism — proposed short peptide–DNA interaction driving tissue-selective gene expression.
- Evidence quality — single-tradition and largely preclinical; preliminary.

## FAQs

### What is Cardiogen?

Cardiogen is a synthetic Ala-Glu-Asp-Arg tetrapeptide studied as a cardiac-tissue bioregulator in the Khavinson short-peptide series.

### What tissue is it associated with?

The myocardium (heart muscle) — each bioregulator in the series is framed around a specific target tissue.

### How strong is the evidence?

It is concentrated in a single research tradition and is largely preclinical, so findings are preliminary. This page is a research and educational reference.

## Latest research

Recent trials and publications mentioning Cardiogen, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [Cardiovascular Genistein Therapy for Heart Failure Inflammation](https://clinicaltrials.gov/study/NCT06501768) — RECRUITING · PHASE1, PHASE2 · NCT06501768
- [Genetics of Cardiovascular Disease](https://clinicaltrials.gov/study/NCT06253481) — UNKNOWN · NCT06253481
- [OPTImal Treatment of Sinus VENOSUS Defect](https://clinicaltrials.gov/study/NCT05865119) — RECRUITING · NA · NCT05865119
- [Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning](https://clinicaltrials.gov/study/NCT01424774) — COMPLETED · NCT01424774

---

Source: AmericanPeptide.com — https://www.americanpeptide.com/catalog/cardiogen
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.